-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 28, the latest NMPA approval document showed that Shandong Lukang Pharmaceutical and Dapagliflozin of Beijing Fuyuan Pharmaceutical were approved for listing at the same time
.
Previously, dapagliflozin was only approved in the domestic original research, this time this product finally ushered in the first imitation
Dapagliflozin is an SGLT2 inhibitor hypoglycemic drug developed by AstraZeneca
.
SGLT-2 inhibitors can prevent the glucose in the renal tubules from being reabsorbed into the blood smoothly, but are excreted in the urine, thereby reducing the blood glucose concentration
In 2014, dapagliflozin was approved by the FDA for the first time and has been approved for 3 indications for type 2 diabetes, heart failure, and lower ejection fraction
.
In March 2017, dapagliflozin was approved for import for the first time and was listed in China
Dapagliflozin is one of AstraZeneca's heavyweight varieties
.
Insight database shows that in 2020 its global sales have reached 1.
Daglienet annual sales
From: Insight database (http://db.
dxy.
cn/v5/home/)
From the perspective of domestic generic drug competition, Dapagliflozin currently has 24 generic drug companies
.
In addition to Lukang Pharmaceutical and Fuyuan Pharmaceutical, which were approved today, domestic companies such as Hausen, Chengdu Better, and Shuanglu Pharmaceutical have applied for listing; five companies including Nanjing Tianqing are also in the BE trial stage
Dalglienet competitive landscape (Insight)
From: Insight database (http://db.
